Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENID: Dose De-escalation for HPV+ Oropharyngeal Cancer
NCT04444869Phase 2Recruiting
- Sponsor
- University of Missouri
- Start
- Sep 2020
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Missouri. Primary endpoint: Rate of PEG tube placement. Started Sep 2020; status: recruiting.
Beyond the preview
Go deeper on NCT04444869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444869.